Primary prophylaxis with G-CSF is recommended by international guidelines to reduce the frequency, severity, duration and risk of chemotherapy-induced neutropenia when the risk associated with FN is ≥20% [1,3]. The gene discussed is CSF3; the disease is neutropenia.